LEADER 01278nam  2200373Ka 450 
001 9910696173503321
005 20070911095313.0
035   $a(CKB)5470000002375074
035   $a(OCoLC)170923820
035   $a(EXLCZ)995470000002375074
100   $a20070911d2002      ua             0
101 0 $aeng
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aHuman subject protection$b[electronic resource] $ethe FDA's role in a system of safeguards
205   $aRev. Feb. 2002.
210  1$aRockville, MD :$cDept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs,$d[2002]
215   $a1 sheet $cdigital, PDF file
225 1 $aJust the facts
225 1 $aPublication ;$vno. FS 01-11
300   $aTitle from title screen (viewed Sept. 10, 2007)
517   $aHuman subject protection 
606   $aHuman experimentation in medicine
606   $aClinical trials
615  0$aHuman experimentation in medicine.
615  0$aClinical trials.
712 02$aUnited States.$bFood and Drug Administration.$bOffice of Public Affairs.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696173503321
996   $aHuman subject protection$93509690
997   $aUNINA